Key Highlights

  • Zivo Bioscience develops therapeutic and nutritional products from proprietary algal cultures for animal, human and supplement markets.
  • The company transitioned to the OTCID marketplace in May 2026 after previously trading on the OTCQB market.
  • Its research includes avian-influenza mitigation and poultry coccidiosis studies referenced with the University of Delaware.

Sharp single-day drops in a small, tightly held research company can look alarming without necessarily signaling anything new about the science. Zivo Bioscience, Inc. (ZIVO) reportedly fell around 14% in a recent session, yet there is no verifiable company announcement tied to that specific move. For an over-the-counter biotech-and-agtech venture with a compact share count and a modest market value, double-digit swings can reflect low Liquidity as much as any shift in the underlying story.

Company and Latest Development

Zivo Bioscience develops therapeutic and nutritional products derived from proprietary algal cultures, targeting animal health, human health and dietary-supplement markets. Its intellectual property centers on proprietary algal strains and patented production techniques. A notable structural development came in May 2026, when the company transitioned to the OTCID marketplace, having previously traded on OTCQB. On the research side, Zivo has publicized work aimed at avian-influenza mitigation and poultry coccidiosis, including studies referenced with the University of Delaware and collaborations tied to animal-health applications. These programs position the company as an early-stage developer straddling the biotechnology and agricultural-technology sectors rather than a commercial-scale operator.

What Is Driving Attention Around ZIVO?

The supplied headline flags a roughly 14% decline, but no confirmed press release, filing or trial result explains that particular session. In a thinly traded OTC security with a small float, a move of that magnitude can be produced by limited Volume and normal micro-cap Volatility rather than fresh news. The honest assessment is that the drop had no single, clearly identifiable public catalyst. Attention around ZIVO more broadly reflects its niche algae-based research programs, its recent marketplace transition, and the speculative interest that tends to accompany small, science-driven names with long development timelines.

Key Numbers and Company Position

Verifiable figures point to a small, pre-commercial company. Aggregated data placed the shares near $3.11 in early September 2026, with a market Capitalization around $12–13 million and a small share count of roughly 4 million shares outstanding. Trailing Revenue was modest, reported near the low hundreds of thousands of dollars, and the company was operating at a net loss. Zivo trades on the OTC market rather than a national exchange, which typically means lighter liquidity and wider price swings. The Market Value has contracted substantially from prior levels, reflecting the funding pressures common to early-stage developers.

What Could Come Next?

Investors tracking Zivo may watch for data from its avian-influenza and coccidiosis research, updates on collaborations with academic and animal-health partners, and any move toward commercialization or licensing of its algal-derived products. Progress in the dietary-supplement and animal-health channels, along with any Partnership or distribution agreements, would be meaningful for a company of this size. Because it is pre-commercial with limited revenue, financing developments, any capital raise or strategic transaction, would also be material to sentiment.

Risks to Watch

The risk profile is high. As an early-stage developer with minimal revenue and ongoing losses, Zivo faces funding pressure and potential dilution from future raises. OTC listing brings Liquidity Risk and pronounced price volatility, where large percentage moves can occur on light volume. Scientific and regulatory uncertainty surrounds its research programs, and translating algal-culture technology into commercial products carries execution and market-adoption risk. Competition in animal health and supplements adds further pressure.

Conclusion

Zivo Bioscience is a small, OTC-traded algae-technology developer whose reported 14% drop lacks a confirmed catalyst and may owe more to thin liquidity than to any change in fundamentals. The items worth monitoring are concrete: research readouts in avian influenza and poultry health, partnership and commercialization progress, and the company's funding position following its 2026 marketplace transition. For ZIVO, evidence of real product traction and adequate capital will likely matter far more than any single volatile session.